SDO, UKM to start trial for fatty liver disease treatment


PETALING JAYA: Sime Darby Oils (SDO), the downstream unit of Sime Darby Plantation Bhd announced a collaboration via a memorandum of agreement with Universiti Kebangsaan Malaysia (UKM) to begin the world’s first clinical trial to determine tocotrienols which is derived from palm oil could be used as a therapeutic approach for the treatment of non-alcoholic fatty liver disease (NAFLD).

“This is potentially a very exciting development for us which if the results are favorable could lead to tocotrienols being prescribed as a medicine for NAFLD, ” SDO’s managing director, Mohd Haris Mohd Arshad said at a press conference after the announcement yesterday.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

BNM governor: Ringgit in right direction despite uncertainties caused by US trade war
He Group confident of sustaining growth momentum
Maybank appoints Malique Sidique as acting GCFO
SMRT eyes growth in key markets, expands footprint
Ringgit firmer against US dollar on sustained hope for Fed rate cut
Johor Plantations posts higher net profit of RM257.32mil for FY24
Teo Seng Capital expects stable performance for the year
EcoWorld sells land in Johor to Microsoft for RM693mil
Chemlite Innovation Bhd receives Bursa Securities approval for ACE Market listing
Bursa Malaysia ends lower, RichTech Digital surges 28%

Others Also Read